Inmaculada Hernandez, PharmD, PhD

Regardless of the number of manufacturers, generic drug prices presented double-digit average increases from 2012 to 2015.

The results of the study demonstrate the potential of provider-led health plans to deliver high-quality care and patient satisfaction. The relationships between these plans and outcomes differed by plan size, nonprofit status, and region.

The annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.